Medical Adhesives and Sealants Market Size, Trends and Growth Analysis by 2027

The global market for medical foods designed for inborn errors of metabolism is projected to grow significantly, reaching an estimated US$ 5,768.79 million by 2027, up from US$ 2,507.80 million in 2019. This growth represents a compound annual growth rate (CAGR) of 11.2% from 2020 to 2027.

Several factors are driving this expansion, including the rising prevalence of inborn errors of metabolism and an increasing consumer inclination towards dietary supplements. However, the market may face challenges due to certain issues associated with medical foods for these metabolic disorders during the forecast period.

There is a noticeable shift in consumer preference towards nutraceutical supplements and prescribed medical foods over traditional enzyme-based therapies. This trend is influenced by escalating healthcare costs and a growing desire for straightforward and effective solutions for managing health conditions. Medical foods are specifically formulated products used in the dietary management of various diseases, including inborn errors of metabolism, and they contain essential nutrients tailored to meet the needs of patients with specific conditions.

The U.S. Food and Drug Administration (FDA) classifies medical foods into four primary categories: formulas for metabolic disorders, complete nutritional products, nutritionally incomplete products, and oral rehydration solutions. These medical foods are readily accessible as they do not require a prescription, although they should be consumed under medical supervision. In the context of inborn errors of metabolism, these foods serve as therapeutic options, and the products available are regulated under strict food and dietary supplement guidelines.

Nutritional treatments for inborn errors of metabolism can provide between 85% and 90% of the nutritional needs for individuals with specific inherited disorders. Additionally, these supplements typically have minimal side effects, making them suitable for patients across all age groups. Recently, private medical insurers in the U.S. and other countries have begun offering reimbursement programs for certain medical foods, further encouraging their adoption. Consequently, the increasing use of medical foods and nutrient supplements is expected to significantly contribute to market growth during the forecast period.

The global market for medical foods for inborn errors of metabolism is categorized based on several factors, including product type, age group, disease type, form, packaging, distribution channels, and geographical regions. In terms of product type, the market includes categories such as amino acids, glytactin with GMP, amino acid-modified infant formulas with iron, low-calcium/vitamin D-free infant formulas with iron, low-protein foods, and others. In 2019, the amino acid segment held the largest market share, driven by the availability of a wide range of amino acid-based products and their increasing demand. The prevalence of amino acid disorders is notably high, which is expected to further boost the demand for these products in the coming years.

When segmented by age group, the market includes infants, weaning children, adolescents, and adults. In terms of disease categories, the market encompasses conditions such as Phenylketonuria (PKU), Maple Syrup Urine Disease (MSUD), Homocystinuria, Urea Cycle Disorders, Methylmalonic Acidemia, Organic Acidurias, Propionic Acidemia, Isovaleric Acidemia, Disorders of Leucine Metabolism, Glutaric Acidemia Type I, Renal Disease, Tyrosinemia Types I and II, among others. The market is also segmented by product form, which includes powders, liquids, gels, and other formats. Packaging options consist of cans, jars, packets, bottles, and more. Distribution channels include retail pharmacies, hospital pharmacies, online pharmacies, drug stores, and other outlets.

To compile this report, several key secondary sources were consulted, including the Food and Drug Administration (FDA), World Health Organization (WHO), Organization for Economic Co-operation and Development, South Asia Food and Nutrition Security Initiative (SAFANSI), Public Health England (PHE), International Trade Administration (ITA), and the Chinese Rare Disease Research Consortium (CRDRC).